Impact of curcumin in Non-alcoholic fatty liver disease

Impact of curcumin capsules on serum levels of pro-inflammatory,anti-inflammatory cytokines and cell adhesion molecules in Non-alcoholic fatty liver disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201702209662N12

Enrollment

Registered

2017-04-25

Start date

2016-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Nonalcoholic fatty liver disease (NAFLD). Condition 2: Other specified inflammatory liver diseases. Fatty (change of) liver, not elsewhere classified Other specified inflammatory liver diseases

Interventions

Intervention 1: A number of curcumin capsules daily (500 mg) for 8 weeks. Intervention 2: A number of placebo capsules daily (500 mg) for 8 weeks.

Treatment - Drugs

Placebo

A number of curcumin capsules daily (500 mg) for 8 weeks

A number of placebo capsules daily (500 mg) for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Adult subjects with symptoms of metabolic syndrome including waist circumference greater than 102 cm (male) or greater than 88cm (female); blood pressure greater than or equal 130/ 85 mmHg; triglycerides greater than 150 mg/dl; high-density lipoprotein cholesterol (HDL-C) less than 40 mg/d (males) or less than 50 mg/d (females); and fasting blood glucose greater than 100 mg/dL were screened for eligibility. Also inclusion criteria were diagnosis of NAFLD (grades 1–3) according to liver ultrasonography. Exclusion criteria: will be pregnancy or breastfeeding; NAFLD secondary to alcohol consumption; smoking, consumption of hypoglycemic; hypolipidemic; and anti-inflammatory medications as well as any drug known to affect hepatic function; and the presence of hepatitis; coronary; renal; pulmonary; and thyroid diseases

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
L-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;E-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;P-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;V CAM-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;I CAM-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-6. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-8. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-10. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;TNF-a. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;VEGF. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;MCP-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.	—

Measure

Time frame

L-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;E-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;P-selectin. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;V CAM-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;I CAM-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-6. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-8. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;IL-10. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;TNF-a. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;VEGF. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.;MCP-1. Timepoint: Before and 8 weeks after intervention. Method of measurement: ELISA Kit.

—

Secondary

Measure	Time frame
Grade of fatty liver. Timepoint: Before and 8 weeks after intervention. Method of measurement: Ultrasonography.;BMI. Timepoint: Before and 8 weeks after intervention. Method of measurement: Kg/m2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Amir Hossin Sahebkar

Mashhad University of Medical Sciences

SahebkarA@mums.ac.ir+98 51 3841 1538

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026